Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 4/20 | 0.42 |
| ▸ | TP53 | P04637 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.37 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.35 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.35 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.33 |
| ▸ | GRIA1 | P42261 | 2/20 | 0.33 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.33 |
| ▸ | GRIA3 | P42263 | 2/20 | 0.33 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.33 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | GRIK3 | Q13003 | 1/20 | 0.33 |
| ▸ | GRIK4 | Q16099 | 1/20 | 0.33 |
| ▸ | GRIK5 | Q16478 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2476367 | 0.74 | HCRTR2 (0.42) | HCRTR1RAB9ASMN1; SMN2HCRTR2HTT | |
| SCHEMBL19207092 | 0.73 | CSNK2A1 (0.44) | HCRTR1TP53RAB9ASMN1; SMN2HCRTR2 | |
| SCHEMBL31336940 | 0.73 | CSNK2A1 (0.44) | HCRTR1TP53RAB9ASMN1; SMN2HCRTR2 | |
| SCHEMBL30775045 | 0.73 | HCRTR2 (0.50) | HCRTR1HCRTR2 | |
| SCHEMBL264270 | 0.73 | HCRTR2 (0.50) | HCRTR1HCRTR2 | |
| SCHEMBL607037 | 0.72 | HCRTR2 (0.49) | HCRTR1HCRTR2 | |
| SCHEMBL2471955 | 0.72 | HCRTR2 (0.42) | HCRTR1SMN1; SMN2HCRTR2MEN1KMT2A | |
| SCHEMBL3385656 | 0.72 | HCRTR2 (0.41) | HCRTR1HCRTR2KMT2A | |
| Lithium SCHEMBL607039 | 0.72 | HCRTR2 (0.49) | HCRTR1HCRTR2 | |
| SCHEMBL31372446 | 0.72 | HCRTR2 (0.41) | HCRTR1HCRTR2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12084437-B2 | Halo-substituted piperidines as orexin receptor modulators | ASTRAZENECA AB (SE) | 2024-09-10 | — | — | US | disclosed |
| US-20220380359-A1 | HALO-SUBSTITUTED PIPERIDINES AS OREXIN RECEPTOR MODULATORS | NIUVERA BIO, INC. | 2022-12-01 | — | — | US | disclosed |
| US-11434236-B2 | Halo-substituted piperidines as orexin receptor modulators | ASTRAZENECA AB (SE) | 2022-09-06 | — | — | US | disclosed |
| EP-3414241-B1 | HALO-SUBSTITUTED PIPERIDINES AS OREXIN RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2022-05-04 | — | — | EP | disclosed |
| EP-3414241-B1 | HALO-SUBSTITUTED PIPERIDINES AS OREXIN RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2022-05-04 | — | — | EP | disclosed |
| CN-109219606-B | Halogen substituted piperidines as orexin receptor modulators | 阿斯利康(瑞典)有限公司 | 2021-10-01 | — | — | CN | disclosed |
| US-20210214348-A1 | HALO-SUBSTITUTED PIPERIDINES AS OREXIN RECEPTOR MODULATORS | NIUVERA BIO, INC. | 2021-07-15 | — | — | US | disclosed |
| US-20210214348-A1 | HALO-SUBSTITUTED PIPERIDINES AS OREXIN RECEPTOR MODULATORS | NIUVERA BIO, INC. | 2021-07-15 | — | — | US | disclosed |
| US-10894789-B2 | Halo-substituted piperidines as orexin receptor modulators | ASTRAZENECA AB (SE) | 2021-01-19 | — | — | US | disclosed |
| US-10894789-B2 | Halo-substituted piperidines as orexin receptor modulators | ASTRAZENECA AB (SE) | 2021-01-19 | — | — | US | disclosed |
| US-20190135800-A1 | HALO-SUBSTITUTED PIPERIDINES AS OREXIN RECEPTOR MODULATORS | EOLAS THERAPEUTICS, INC. | 2019-05-09 | — | — | US | disclosed |
| US-20190135800-A1 | HALO-SUBSTITUTED PIPERIDINES AS OREXIN RECEPTOR MODULATORS | EOLAS THERAPEUTICS, INC. | 2019-05-09 | — | — | US | disclosed |
| EP-3414241-A1 | HALO-SUBSTITUTED PIPERIDINES AS OREXIN RECEPTOR MODULATORS | Astrazeneca AB (SE) | 2018-12-19 | — | — | EP | disclosed |
| WO-2017139603-A1 | HALO-SUBSTITUTED PIPERIDINES AS OREXIN RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2017-08-17 | — | — | WO | disclosed |
| WO-2017139603-A1 | HALO-SUBSTITUTED PIPERIDINES AS OREXIN RECEPTOR MODULATORS | ASTRAZENECA AB (SE) | 2017-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10894789-B2 | Halo-substituted piperidines as orexin receptor modulators | HCRTR2, HCRTR1, OPRD1 | HCRTR1 2/4885TP53 4881/4885RAB9A 1324/4885 |
| US-11434236-B2 | Halo-substituted piperidines as orexin receptor modulators | HCRTR2, HCRTR1, OPRD1 | HCRTR1 2/4885TP53 4881/4885RAB9A 1324/4885 |
| US-20190135800-A1 | HALO-SUBSTITUTED PIPERIDINES AS OREXIN RECEPTOR MODULATORS | HCRTR2, HCRTR1, OPRD1 | HCRTR1 2/4885TP53 4881/4885RAB9A 1324/4885 |
| US-20220380359-A1 | HALO-SUBSTITUTED PIPERIDINES AS OREXIN RECEPTOR MODULATORS | HCRTR2, HCRTR1, OPRD1 | HCRTR1 2/4885TP53 4881/4885RAB9A 1324/4885 |
| US-12084437-B2 | Halo-substituted piperidines as orexin receptor modulators | HCRTR2, HCRTR1, OPRD1 | HCRTR1 2/4885TP53 4881/4885RAB9A 1324/4885 |
| US-20210214348-A1 | HALO-SUBSTITUTED PIPERIDINES AS OREXIN RECEPTOR MODULATORS | HCRTR2, HCRTR1, OPRD1 | HCRTR1 2/4885TP53 4881/4885RAB9A 1324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.